Acellular pertussis vaccines for adolescents

Jornal de Pediatria

Volumn 82, Issue SUPPL. 1, 2006, Pages

  De Carvalho, Aroldo P ^a,b,c,f   Pereira, Eliane Mara Cesário ^d,e  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDADE DO VALE DO ITAJAÍ   (Brazil)

^c HOSPITAL INFANTIL JOANA DE GUSMÃO   (Brazil)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e POSITIVO UNIVERSITY   (Brazil)

^f NONE   (Brazil)

Author keywords

Acellular vaccine; Pertussis; Pertussis vaccine; Vaccine for adolescents; Whooping cough

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FIMBRIA PROTEIN; HEMAGGLUTININ; PERTACEL; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; REFORTRIX; UNCLASSIFIED DRUG;

BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; BRAZIL; CANADA; CLINICAL FEATURE; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LABORATORY DIAGNOSIS; PERTUSSIS; PRACTICE GUIDELINE; PREVALENCE; REVIEW; TREATMENT DURATION; VACCINATION; ADOLESCENT; ADULT; CHILD; DIPHTHERIA; IMMUNOLOGY; PATHOGENICITY; TETANUS;

ADOLESCENT; ADULT; BORDETELLA PERTUSSIS; BRAZIL; CHILD; DIPHTHERIA; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; PERTUSSIS VACCINE; TETANUS; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 33750518385     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1491     Document Type: Review

References (54)

1. Smith C, Vyas H. Early infantile pertussis: increasingly prevalent and potentially fatal. Eur J Pediatr. 2000;159:898-900.
2. Crowcroft NS, Booy R, Harrison T, Spicer L, Britto J, Mok Q, et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child. 2003;88:802-6.
3. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J. 2003;22:628-34.
4. Mikelova LK, Halperin SA, Scheifele D, Smith B, Ford-Jones E, Vaudry W, et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr. 2003;143:576-81.
5. Torvaldsen S, McIntyre PB. Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr Infect Dis J. 2003;22:956-9.
6. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J. 2005;24(6 Suppl):S104-8.
7. Baptista PN, Magalhães V, Rodrigues LC, Rocha MA, Pimentel AM. Source of infection in household transmission of culture-confirmed pertussis in Brazil. Pediatr Infect Dis J. 2005;24:1027-8.
8. Locht C. Molecular aspects of bordetella pertussis pathogenesis. Int Microbiol. 1999;2:137-44.
9. Heininger U. Recent progress in clinical and basic pertussis research. Eur J Pediatr. 2001;160:203-13.
10. Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshal GS, Bologa M, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA. 2005;293:3003-11.
11. Edelman KJ, He Q, Makinen JP, Haanpera MS, Tran Minh NN, Schuerman L, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis. 2004;39:179-85.
12. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58-61.
13. Laing JS, Hay M. Whooping-cough: its prevalence and mortality in Aberdeen. Public Health. 1902;14:584-98.
14. Gordon JE, Hood RI. Whooping cough and its epidemiological anomalies. Am J Med Sci. 1951;222:333-61.
15. Wirsing von König CH, Postels-Multani S, Bock HL, Schmitt HJ. Pertussis in adults: frequency of transmission after household exposure. Lancet. 1995;346:1326-9.
16. Miller E, Gay NJ. Epidemiological determinants of pertussis. Dev Biol Stand. 1997;89:15-23.
17. Versteegh FG, Schellekens JF, Nagelkerke AF, Roord JJ. Laboratory-confirmed reinfections with Bordetella pertussis. Acta Paediatr. 2002;91:95-7.
18. World Health Organization. Pertussis vaccines - WHO position paper. Wkly Epidemiol Rec. 2005;80:31-9.
19. Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, et al. Randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 1997;15:1606-12.
20. Tindberg Y, Blennow M, Granstrom M. A ten year follow-up after immunization with a two component acellular pertussis vaccine. Pediatr Infect Dis J. 1999;18:361-5.
21. Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics. 2001;108:E81.
22. Lugauer S, Heininger U, Cherry JD, Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr. 2002;161:142-6.
23. Forsyth K, Tan T, von König CH, Caro JJ, Plotkin S. Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J. 2005;24(5 Suppl):S69-74.
24. Schellekens J, Von König CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J. 2005;24(5 Suppl):S19-24.
25. Halperin SA. Pertussis - a disease and vaccine for all ages. N Engl J Med. 2005;353:1615-7.
26. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J. 2005;24(5 Suppl):S10-8.
27. World Health Organization. Control of diphtheria, pertussis, tetanus, Haemophilus influenzae type b, and hepatitis B: field guide. Washington: WHO; 2005.
28. Cherry JD. The science and fiction of the "resurgence" of pertussis. Pediatrics. 2003;112:405-6.
29. Centers for Disease Control and Prevention (CDC). Pertussis - United States, 1997-2000. MMWR Morb Mortal Wkly Rep. 2002;51:73-6.
30. Brasil, Ministério da Saúde, Secretaria de Vigilância em Saúde. Situação das doenças transmissíveis no Brasil. http://portal.saude.gov.br/portal/svs/area.cfm?id_area=451. Access: 10/08/2004.
31. Baron S, Njamkepo E, Grimprel E, Begue P, Desenclos JC, Drucker J, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use vaccination. Pediatr Infect Dis J. 1998;17:412-8.
32. Halperin SA, Wang EE, Law B, Mills E, Morris R, Dery P, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program - Active (IMPACT). Clin Infect Dis. 1999;28:1238-43.
33. Elliott E, McIntyre P, Ridley G, Morris A, Massie J, McEniery J, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J. 2004;23:246-52.
34. Carvalho AP. Mesa redonda: vigilância epidemiológica. Coqueluche. In: XIV Congresso Brasileiro de Infectologia Pediátrica; 2005 abr 27-30; Foz do Iguaçu, Brasil.
35. Wirsing von König CH, Postels-Multani S, Bogaerts H, Bock HL, Laukamp S, Kiederle S, et al. Factors influencing the spread of pertussis in households. Eur J Pediatr. 1998;157:391-4.
36. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics. 1997;100:E10.
37. Liese JG, Renner C, Stojanov S, Belohradsky BH; Munich Vaccine Study Group. Clinical and epidemiological picture of B pertussis and B parapertussis infections after introduction of acellular pertussis vaccines. Arch Dis Child. 2003;88:684-7.
38. Tozzi AE, Rava L, Ciofi degli Atti ML, Salmaso S; Progetto Pertosse Working Group. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics. 2003;112:1069-75.
39. Hoppe JE. Neonatal pertussis. Pediatr Infect Dis J. 2000;19:244-7.
40. World Health Organization. Generic protocol for estimating the burden of pertussis in young children. Geneva: WHO; 2005.
41. a ed. Brasília: Ministério da Saúde; 2005. p. 81-4.
42. Hay JW, Ward JI. Economic considerations for pertussis booster vaccination in adolescents. Pediatr Infect Dis J. 2005;24(6 Suppl):S127-33.
43. Juretzko P, von Kries R, Hermann M, Wirsing von König CH, Weil J, Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis. 2002;35:162-7.
44. Hewlett EL, Edwards KM. Clinical practice. Pertussis - not just for kids. N Engl J Med. 2005;352:1215-22.
45. Davis JP. Clinical and economic effects of pertussis outbreaks. Pediatr Infect Dis J. 2005;24(6 Suppl):S109-16.
46. Halperin SA. Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatr Infect Dis J. 2005;24(6 Suppl):S141-6.
47. Halperin SA, Smith B, Russell M, Hasselback P, Guasparini R, Skowronski D, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine. 2000;18:1312-9.
48. National Advisory Committee on Immunization (NACI). Prevention of pertussis in adolescents and adults. Can Commun Dis Rep. 2003;29:1-9.
49. Cherry JD. Pertussis vaccines for adolescents and adults. Pediatrics. 2005;116:755-6.
50. United States of America, The Advisory Committee on Immunization Practices. Recommended childhood and adolescent immunization schedule - United States, 2006. MMWR. 2006;54:Q1-4.
51. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis. 2004;39:20-8.
52. Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis. 2004;39:1802-9.
53. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353:1555-63.
54. Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J. 2005;24(5 Suppl):S75-82.